2022 ASCO GU Overview: Dr. Stratton highlights top prostate cancer abstracts
Kelly L. Stratton, MD, FACS, highlights 5 pivotal prostate cancer studies from the 2022 ASCO Genitourinary Cancers Symposium.
In this video, Kelly L. Stratton, MD, FACS, highlights notable prostate cancer research being presented at the 2022 ASCO Genitourinary Cancers Symposium. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
The following 5 abstracts are summarized:
Abstract 11: PROpel: Phase III trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer
Abstract 12: Phase III MAGNITUDE study: First results of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with mCRPC with and without homologous recombination repair gene alterations.
Abstract 13: Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
Abstract 9: Detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)
Abstract 15: A randomized, double-blind, placebo-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide in chemotherapy-naïve, metastatic castration-resistant prostate cancer patients treated with docetaxel plus prednisolone who have progressed on enzalutamide: PRESIDE.
Ra223 plus SABR does not delay progression of oligometastatic HSPC
October 3rd 2024"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
